Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is exploring the potential of fibroblasts in a variety of clinical applications and has a diverse pipeline, including product candidates for wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and potential human longevity applications. The company's focus on fibroblast-based therapies is unique and shows promise in addressing unmet medical needs in various chronic diseases. Additionally, FibroBiologics has a strong IP portfolio of over 275 issued and pending patents, providing a deep moat for the company's technology. The upcoming results from the Phase 1/2 trial for fibroblast therapy CYWC628 in diabetic foot ulcer patients could serve as proof-of-concept for the broader clinical applications of fibroblast therapy and potentially de-risk the platform for future development.

Bears say

FibroBiologics is facing near-term negative pressure after its recent downgrade to a Hold following a reverse stock split to maintain compliance with Nasdaq. While the company's fibroblast-based therapies hold potential for chronic diseases, including DFU, psoriasis, and multiple sclerosis, their clinical validation and success are critical for attracting investors. Additionally, potential risks such as clinical and financial risk, partnership challenges, and competition in the market could hinder the company's growth and market share.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.